Friday, November 01, 2019 2:11:42 AM
Thanks Lykira, your posts are always some of the best.
You are suggesting that perhaps improvements were made to DCVax from Germany.
And Iam suggesting that the impovements may have been a colaberation between German hospital and Bosch from NWBO
Anwyways I am surmising the home run we have been waiting for is data on the later enrolled patients.
The reason why they had to run the trial out this long is because statistacily a small number were later enrolled with new method.
So hoping top line data reads out that trial was succesful in progression free survival.Trial was succesful in overall survival.
The last 50 patients enrolled in trial have so far survived 30% longer than our initial patients that have significantly out performed standard of care.
Good luck all believers
You are suggesting that perhaps improvements were made to DCVax from Germany.
And Iam suggesting that the impovements may have been a colaberation between German hospital and Bosch from NWBO
Anwyways I am surmising the home run we have been waiting for is data on the later enrolled patients.
The reason why they had to run the trial out this long is because statistacily a small number were later enrolled with new method.
So hoping top line data reads out that trial was succesful in progression free survival.Trial was succesful in overall survival.
The last 50 patients enrolled in trial have so far survived 30% longer than our initial patients that have significantly out performed standard of care.
Good luck all believers
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
